10647 results for 'secondary antibody HRP'

A macrophage does not decide to eat; it counts votes. Every particle it touches carries a mixture of pro-phagocytic and inhibitory ligands, and engulfment follows only when the activating tally clear

What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,

Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD

In the periphery, co-stimulation rescues a T cell. In the thymus, the same molecules kill it. A peripheral T cell that engages its receptor without CD80 and CD86 becomes anergic; engage them and it r

CD25, a key molecule in immune regulation, is integral to the function of activated lymphocytes and regulatory T cells. It's central in mediating immune responses, with implications in autoimmune

Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression

Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at

Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik

Introduction Discover the multifaceted role of CD33, a critical player in immune function and disease, shaping our approach to treating cancers and neurodegenerative conditions

Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does

Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli

Understanding Lag-3, Tim-3, and TIGIT: Key Players in T Cell RegulationThe immune system's ability to regulate T cell responses is crucial for maintaining homeostasis and combating diseases such as ca

What is CD52? Cluster Of Differentiation 52 (CD52) is a highly expressed membrane glycoprotein which is present on the surface of immune cell

PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are

The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.

The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public healt

Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons